

Absent any showing or evidence that the claims of Groups I, II, and III lack a common technical feature, Applicants request rejoinder of these groups. Applicants further request rejoinder of Group V, which is directed to methods of administering pharmaceutical compositions of Group I, upon allowance of claims directed to reconstituted Group I (e.g., claims 1-17 and 20-23).


Solely for the purposes of providing a fully responsive submission, Applicants hereby provisionally elect Group I, claims 1, 2, 5-7, 10, 13-15, drawn to a precipitate comprising an anionic polymeric component and an amphiphilic ammonium-type component. Applicants make this election with traverse. To be clear the traverse is as the restriction is applied to the composition of matter and method of treatment claims (Groups I-III and V) and medical device claims (Group IV) is not traversed.

Applicants request that the restriction requirement as it applies to the composition of matter claims be withdrawn and that claims 1-17 and 20-23 be examined on the merits.

Applicants request rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention, e.g., Applicants respectfully request rejoinder of the subject matter corresponding to Groups V upon allowance of the claims embodying the elected invention.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3105



John Alexander
Attorney for Applicants
Reg. No. 48,399

Date:

30 November 2007